Do your own DD. Never buy or sell based on my posts. Consult a licensed securities broker before you buy or sell any security.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Keep up the great work posting solid information on multiple fronts
We appreciate your efforts
TFUEL BUSTS .05
Why isn't this place crawling with craziness???
Keep up the good work
cc @ARKInvest @CathieDWood #DMD $CAPR $SRPT https://t.co/A7ls2SPxfE
— Rogerthat1 (@rogerthat191) February 12, 2021
From .0006 x .0007 to .00065 x .0007
Inching upwards ....
Never mind .... dropped back to .0006 x .0007
I've held this stinky pinky for a loooooong time. It stayed dormant in my account, languishing ....
Imagine my surprise when it was recently resurrected. Oh what joy .... such elation .... but why? Who knows? Who cares?
Is it a RS? A reverse merger? A P&D? Time will tell ....
.... I just threw more money at it and it moved .... so here's hoping for the best outcome ....
Is this good money chasing after bad? Again, time will tell ...
If you put your money in something like this with little to no information available, be prepared to have it all be gone .... that's why it is considered a Caveat Emptor stock.
I put mine on red ....
Its like putting a couple hundred dollars on the roulette table
RED
no wait
BLACK
Look at all of the big names affiliated with Capricor
- Johns Hopkins
- Cedars Sinai https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157616644
- Dr. Gould https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157270067
- BlackRock https://stocktwits.com/MasterChi/message/255893266
- HC Wainright and the Wainright Charities https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158230556
- US Dept of Defense
- Lanza Manufacturing https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157666641
Then there is stuff like this
- https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159489390
- Rare Drug Designation
- They are HIRING https://capricor.com/careers/
Want more Capricor Patent information? Try Google
https://patents.google.com/?assignee=Capricor&oq=Capricor
Search of Capricor on the Patent and Trademark Website gets this:
PUB. APP. NO. Title
1 20210032598 ACTIVATION-INDUCED TISSUE-EFFECTOR CELLS SUITABLE FOR CELL THERAPY AND EXTRACELLUAR VESICLES DERIVED THEREFROM
2 20210008150 PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS
3 20200289580 METHODS OF TREATING OCULAR INFLAMMATION AND CHEMICAL INJURIES OF THE EYE WITH EXTRACELLULAR VESICLES
4 20200121727 METHODS AND COMPOSITIONS FOR TREATING SKELETAL MUSCULAR DYSTROPHY
5 20200054686 METHODS OF TREATING SYSTEMIC GRAFT-VERSUS-HOST DISEASE WITH EXTRACELLULAR VESICLES
6 20190099370 METHOD OF PREVENTING OR TREATING RADIATION-INDUCED DERMATITIS WITH EXTRACELLULAR VESICLES
7 20180321240 METHODS OF MEASURING POTENTIAL FOR THERAPEUTIC POTENCY AND DEFINING DOSAGES FOR AUTOLOGOUS CELL THERAPIES
8 20180282698 GENERATION OF THERAPEUTIC CELLS USING EXTRACELLULAR COMPONENTS OF TARGET ORGANS
9 20180169150 OPTIMIZED METHODS FOR GENERATION OF CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY
10 20170363623 METHODS OF MEASURING POTENTIAL FOR THERAPEUTIC POTENCY AND DEFINING DOSAGES FOR AUTOLOGOUS CELL THERAPIES
11 20170360842 PROCESSES FOR PRODUCING STABLE EXOSOME FORMULATIONS
12 20160324930 SYSTEMS AND METHODS FOR THERAPY OF KIDNEY DISEASE AND/OR HEART FAILURE USING CHIMERIC NATRIURETIC PEPTIDES
13 20160317622 Methods of Treatment of Heart Failure With Natriuretic Peptides
14 20160287638 ISCHEMIC TOLERANT CELLS AND CELLULAR FACTORS IN THE TREATMENT OF PERIPHERAL ARTERY DISEASE
15 20160160181 PROCESSES FOR PRODUCING EXOSOMES IN REDUCED OXYGEN CULTURE CONDITIONS
16 20160158291 PROCESSES FOR PRODUCING STABLE EXOSOME FORMULATIONS
17 20160051632 Chimeric Natriuretic Peptide Compositions and Methods of Preparation
18 20150216905 OPTIMIZED METHODS FOR GENERATION OF CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY
19 20150190473 THERAPY FOR KIDNEY DISEASE AND/OR HEART FAILURE
20 20150118199 METHODS OF MEASURING POTENTIAL FOR THERAPEUTIC POTENCY AND DEFINING DOSAGES FOR AUTOLOGOUS CELL THERAPIES
21 20120039857 SYSTEMS AND METHODS FOR CARDIAC TISSUE REPAIR
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Capricor&FIELD1=&co1=AND&TERM2=&FIELD2=&d=PG01
DIG THROUGH AND DO YOUR OWN DD ...
Exosomes isolated from human cardiosphere–derived cells attenuate pressure overload–induced right ventricular dysfunction
From 2019
https://www.sciencedirect.com/science/article/abs/pii/S0022522320324855
Capricor’s COVID-19 success gets FDA and market attention
https://www.bioworld.com/articles/434747-capricors-covid-19-success-gets-fda-and-market-attention
"In one month, the six patients, all suffering from acute respiratory distress syndrome received I.V. infusions of 150 million allogeneic cardiosphere-derived cells. Of the five who were on ventilators, four no longer needed them within one to four days following the infusion, the company said. The fifth remains on mechanical ventilation, and the sixth patient is receiving supplemental oxygen and is listed as clinically stable. Four of the six have been discharged from Cedars-Sinai.
Laboratory biomarkers correlated with poor outcomes were measured in all six patients. Following the infusion, several patients showed improvements in biomarkers such as ferritin, absolute lymphocyte counts and C-reactive protein. No adverse events related to the administration of CAP-1002 were observed.
Capricor said CAP-1002’s immune-modulatory properties could be at the center of reining in an overstimulated immune system by modulating various inflammatory cytokines and regulating the immune response. It’s possible that the body’s overreaction to COVID-19, rather than the virus itself, can lead to death, the company added."
We were here before the Israelis
Fantastic article on exosomes. Great CAPR info here also.
Exosome redux - from https://www.nature.com/articles/s41587-019-0326-5?proof=trueMay
"Capricor is also on track to move its lead exosome program, CAP-2003, which consists of exosomes derived from cardiosphere-derived cells (CDCs), into the clinic in the first half of 2020, says CEO Marbán. The company has completed phase 2 with its allogeneic CDCs for Duchenne muscular dystrophy (DMD), which have been in clinical development for a decade. According to Marbán, exosomes produced by the CDCs have the potential to be a next-generation DMD therapy in their own right. In a DMD mouse model, the exosomes “home to sites of injury, they’re taken up by macrophages, and they change the manifestation of the macrophages from pro-inflammatory to anti-inflammatory.” In August, the company published a paper showing how they can immortalize CDCs and engineer them to produce EVs enriched with miR-92a, a microRNA that promotes signaling of bone morphogenetic protein 2, an antifibrotic ß-catenin target, in rat cardiac cells. Previous attempts to immortalize CDCs resulted in decreased Wnt–ß-catenin signaling and therapeutic potency, but by restoring Wnt–ß-catenin signaling activity using 6-bromoindirubin-3'-oxime, a reversible inhibitor of the ß-catenin suppressor glycogen synthase kinase-3ß, CDC-derived exosomes will be “better therapeutic candidates,” says Marbán.
Several publications have shown the safety of CDC-derived exosomes. These include a 2016 paper showing human CDCs are highly immunogenic in pig models of myocardial infarction, whereas their exosomes are not. This safety profile, combined with the immunomodulatory effects seen with the CDCs and their exosomes, has given Capricor several possible indications to explore with CAP-2003 in the clinic next year. Marbán says the company is still weighing indications that respond to either systemic or local exosome delivery, as well as market analyses and potential regulatory options, to determine which disease to tackle in humans first."
From 2019
The 4 Ways CAPR Works in Vaccines, as Opposed to One Most Others Do
"CAPR targets the spike (S), enevlope (E), membane (M), and nucleocapsid (N) proteins - most others target only the spike"
https://stocktwits.com/prestonwillson/message/240101247
THERE ARE NO SHARES!
https://whalewisdom.com/stock/nltxd
$2.85!
CAPR
Where is everyone else?
When Coinbase starts trading THETA and TFUEL, this board will be hoppin'
TFUEL & THETA both working towards their 52 week highs
THETA Token Price Chart
THETA Fuel Price Chart
Another nice chart
https://twitter.com/RamsCharts/status/1357458253941256195/photo/1
Thank you
Nothing wrong with taking profits.
Ilike the idea of covering costs and riding free shares for a bit.
Good luck to all.
Howdy!
Congrats to longs.
XWAV .... thoughts on long term price target here?
Athletic Events, Hotels, Concerts, Sports Betting?, Fantasy Sports, HOF Tours, Affiliations with Past and Present Football players, Affiliations with current fantasy football opinion leaders?
The CEO used to work for Disney?
Check all of this out for yourself folks. DO your own DD.
Read my disclaimer below.
HOFV
Do a long term day chart ....
hovering around 3.10 - 3.15 looks like we close two major historical gaps
Look at the long term high of the stock
Hmmmmmm
MUST LISTEN TO THIS INTERVIEW
If you have invested in this company and haven't listened to the interview with the CEO, you will miss out on a TON of information.
$HOFV Hall Of Fame SPAC Stock CEO Interview | SPACs Attack
This will be a fun trade
IMO, after listening to the CEO interview about the focus and growth of the company, this will be a great hold
Exercisable at $6.90 A SHARE?
https://newsfilter.io/a/a211673f53d17b4732b5e9a89bd58c71
"Item 1.01 Entry into a Material Definitive Agreement.
On January 28, 2021, Hall of Fame Resort & Entertainment Company, a Delaware corporation (the “Company”), entered into a binding term sheet (the “Term Sheet”) with IRG, LLC, a Delaware limited liability company that is controlled by the Company’s director Stuart Lichter (“Investor”), pursuant to which the Company agreed to issue and sell to Investor for a purchase price of $15 million (“Purchase Price”) in a private placement (the “Private Placement”) (i) shares of a new series of preferred stock of the Company (the “Private Placement Preferred Stock”), which are convertible into shares of the Company’s common stock, par value $0.0001 (the “Common Stock”), having an aggregate liquidation preference of $15 million, and (ii) a number of warrants, exercisable for shares of Common Stock at an exercise price of $6.90 per share (the “Private Placement Warrants”), constituting 50% warrant coverage. The number of warrants to be issued will equal half of the liquidation preference of the Private Placement Preferred Stock divided by the closing price of the Common Stock on a specified date (the “Common Stock Value”). The Private Placement Preferred Stock and Private Placement Warrants are subject to the conversion terms and exercise terms, respectively, described in Item 3.02 hereof. The Private Placement is expected to close by February 26, 2021."
Folks ....
The couple of million of shares bought around 3 pm should tell you something .....
Would one of the Mods please put the following information in the intro section?
https://hofexperiences.com/
Interesting to say the least
On another not, I am wondering why TFUEL is appreciating more than THETA. Any insights?
According to that link you sent, and I just reposted, it sounds like there is some conference coming up with deep pocket investors.
Some of the folks on the feed suggest TFUEL and THETA might start moving after.
We shall see.
Theta Labs' Wes Levitt AMA with Crypto.com with BD1111 (Theta Network)